Burns J W & Co. Inc. NY lowered its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 8.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,158 shares of the medical instruments supplier’s stock after selling 681 shares during the period. Burns J W & Co. Inc. NY’s holdings in Becton, Dickinson and Company were worth $1,624,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Arete Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $767,000. Charles Schwab Investment Management Inc. raised its holdings in Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after acquiring an additional 1,317,723 shares during the last quarter. Centre Asset Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $8,382,000. Nomura Asset Management Co. Ltd. grew its position in shares of Becton, Dickinson and Company by 2.3% in the third quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock valued at $135,267,000 after purchasing an additional 12,845 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Becton, Dickinson and Company by 31.0% in the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after purchasing an additional 673,568 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.
Insiders Place Their Bets
In other news, EVP Shana Carol Neal sold 788 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the sale, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This represents a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,747 shares of company stock valued at $1,949,520 over the last quarter. Company insiders own 0.36% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on BDX
Becton, Dickinson and Company Stock Up 1.1 %
Shares of Becton, Dickinson and Company stock traded up $2.62 during trading on Monday, hitting $236.29. 2,267,624 shares of the stock were exchanged, compared to its average volume of 1,942,473. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42. The stock has a market cap of $68.53 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm’s 50-day moving average price is $226.91 and its 200 day moving average price is $232.45.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were given a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.76%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is 70.03%.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How to Most Effectively Use the MarketBeat Earnings Screener
- Delta Can Fly to New Highs in 2025; Here’s Why
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.